Teva Pharma (TEVA) Launches Generic THIOLA
Get Alerts TEVA Hot Sheet
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 2.1%
Revenue Growth %: +0.8%
Join SI Premium – FREE
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), today announced its launch of the first available generic version, in the U.S., of THIOLA® (tiopronin) tablets, indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine (kidney) stone formation in adults and pediatric patients 9 years of age and older with severe homozygous cystinuria, who are not responsive to these measures alone.
“Teva is pleased to provide patients with first-to-market access to a generic version of THIOLA® (tiopronin) tablets for the prevention of kidney stones, and who are unresponsive to treatment with high fluid intake, alkali, and diet modification,” said Christine Baeder, SVP, Chief Operating Officer US Generics, Teva USA.
With nearly 550 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with approximately 100 pending first-to-files in the U.S. Currently, 1 in 11 generic prescriptions dispensed in the U.S. is filled with a Teva generic product.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mainz Biomed (MYNZ) Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm
- HOOKIPA Pharma Inc. (HOOK) Announces Pivotal Phase 2/3 Trial Design for HB-200 plus Pembrolizumab
- ImmunityBio (IBRX) Announces Positive OS Results of Anktiva Combined With Checkpoint Inhibitors in NSLC
Create E-mail Alert Related Categories
Corporate News, FDARelated Entities
Definitive Agreement, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!